Subarachnoid Hemorrhage

Data on the type of patients enrolled have been described already in other sections.

Subarachnoid haemorrhage

Rosanna Vaschetto

Evaluation of the Level and Prognostic Relevance of New Neuroinflammation Markers in Subarachnoid Haemorrhage

Evaluation of New Neuroinflammation Markers in Subarachnoid Haemorrhage Patients: a Pilot Study

The levels of OPN and microparticles will be related to:
the presence or absence of vasospasm development
the presence or absence of ischemic lesion at the CT-scan
3-6 months outcome evaluated with the GOS-E

Isolated microparticles will be used to activate in vitro renal and pulmonary endothelial cells for the purpose of highlighting a possible cross talk, analyzing endothelial damage markers.

Increase compared to the baseline i.e., day of the bleeding, of OPN level in liquor and blood of patients with SAH measured on days 1, 2, 3, 5, 7, 9, 11.

Rosanna Vaschetto, MD, PhD

Prof.

Azienda Ospedaliero Universitaria Maggiore della Carita

Dantrolene 1.25mg/kg IV every 6 hours x 7 days

Intravenous Datrolene 1.25 mg/kg (includes 5% mannitol) every 6 hours for seven days.

Dantrolene

Equiosmolar volume (5% mannitol) every 6 hours for seven days.

Placebo

Total

Sex: Female, Male

Race/Ethnicity, Customized

Number of subjects who developed hyponatremia (sNa ≤132mmol/L)

Dantrolene 1.25mg/kg IV (includes 5% mannitol) every 6 hours x 7 days

equiosmolar, volume-equivalent sterile water with 5% mannitol every 6 hours x 7 days.

Hyponatremia

Number of subjects who developed liver toxicity as evidenced by Liver Function Test elevation greater than 5 times the upper limit of normal.

equiosmolar, volume-equivalent sterile water with 5% mannitol every 6 hours x 7 days

Liver Toxicity

Number of subjects who expired during hospitalization.

In-hospital Mortality

Dantrolene 1.25mg/kg IV every 6 hours x 7 days
Dantrolene vs. Placebo: Dantrolene 1.25mg/kg IV (includes 5% mannitol) or equiosmolar placebo (5% mannitol) every 6 hours x 7 days

Equiosmolar volume (5% Mannitol)
Dantrolene vs. Placebo: Dantrolene 1.25mg/kg IV (includes 5% mannitol) or equiosmolar placebo (5% mannitol) every 6 hours x 7 days

Overall Study

Dr. Susanne Muehlschlegel

Cerebral Vasospasm

equiosmolar volume (5% mannitol) every 6 hours x 7 days

intracranial aneurysm/phosphatase

Evaluation of the Level and Prognostic Relevance of New Neuroinflammation Markers in Subarachnoid Haemorrhage

Safety Study of Dantrolene in Subarachnoid Hemorrhage

La base de dades d’herbes medicinals més completa avalada per la ciència